David Onions, PhD FMedSCi DVMS(hon) FRSA FRSE, is an investor in biomedical companies and former Chief Medical Officer of Invitrogen/Life Technologies (now Thermo Fisher). He founded 2 biotechnology companies (Q-One Biotech and BioOutsource) which, in total, exited for ˜$100M and he was involved in the buy-out of BioReliance which was sold for $450M to Sigma-Aldrich (now Merck KGaA).
He was formerly a member of the board of BioReliance, VP of its commercial operations and the Chief Scientific Officer of the company. Prior to that he was a founder and President of Q-One Biotech Inc., a company involved in the GMP production and safety evaluation of biotechnology products. The company was awarded the Scottish Council for Development & Industry Award 2002 and the Biotech Scotland Award 2002. In 2003 the company was acquired by Invitrogen (now Thermo-Fisher) where David Onions became the Chief Medical Officer, overseeing the company’s developments of clinically based molecular programs.
In 2007 David was involved in a management buyout of BioReliance from Life Technologies and in 2012 the company was sold to Sigma-Aldrich. He was a co-founder of BioOutsource a rapidly growing service company for the biotechnology industry which was sold to Sartorius in 2015. In 2014 he became a founder director of Citalytics Inc. a company involved in statistical and analysis and unstructured text analysis for Life-Science companies.
Prior to his commercial activities David was Professor of Veterinary Pathology at the University of Glasgow and Director of the Leukaemia Research Fund’s Human Virus Centre.
David Onions is a member or, former member, of several advisory groups including the UK Advisory Committee on Release of GMOs Into the Environment (ACRE), the FDA xenotransplantation advisory committee, The World Health Organisations Expert Advisory Panel on Biological Standardization and The UK Medical Research Council Stem Foundation.
He has been awarded the Norman Hall Gold Medal for Research into Animal Diseases from the Royal College of Veterinary Surgeons, the Animal Health Trust Award for Outstanding Scientific Achievement and The British Veterinary Association’s Dalrympel-Champney Cup and Medal for contributions to veterinary science.
In 2005 he was awarded the Scottish Enterprise award for Leading Individual Contribution to Life Sciences in 2005 and the Invitrogen’s employee of the year (Quest) Award 2005. In 2006 he received an Honorary Doctorate (DVMS) from the University of Glasgow for services to biotechnology and veterinary medicine.
He is a Fellow of the Royal Society of Edinburgh, Fellow of the Academy of Medical Sciences and a Fellow of the Royal Society of Arts.